Interleukin (IL)-13 is a cytokine primarily produced by the T-helper (Th)-2
subset of lymphocytes that possesses powerful anti-inflammatory properties
. Here, we have evaluated the impact of IL-13 treatment on development of t
ype 1 diabetes in diabetes-prone nonobese diabetic (NOD) mice. Prolonged tr
eatment with recombinant human IL-13 (hIL-13) markedly diminished the incid
ence of spontaneous type 1 diabetes in the mice. Female NOD mice treated fr
om age 5-16 weeks with hIL-13 also showed significantly milder insulitis th
an control mice. The preventive action of hIL-13 was associated with a slig
ht but significant change from a type I to a type 2 cytokine response. Acco
rdingly, splenic lymphoid cells (SLC) from hIL-13-treated mice secreted les
s interferon (IFN)-gamma upon ex vivo stimulation with Concanavalin A than
controls, and anti-CD3 monoclonal antibody-induced activation of T-cells in
vivo resulted in lower blood levels of IFN-gamma and tumor necrosis factor
-alpha and augmented blood levels of IL-4 in NOD mice pretreated with hIL-1
3. hIL-13 treatment also increased the blood levels of IgE and inhibited th
e transfer of type 1 diabetes by spleen cells from a diabetic donor to irra
diated recipients. Taken together, these data add hIL-13 to the list of cyt
okines capable of downregulating immunoinflammatory diabetogenic pathways i
n NOD mice, and further support the concept that IL-4-related anti-inflamma
tory cytokines might have a role in the prevention of type 1 diabetes.